1
|
Cohen LE, Hansen CL, Andrew MK, McNeil SA, Vanhems P, Kyncl J, Domingo JD, Zhang T, Dbaibo G, Laguna-Torres VA, Draganescu A, Baumeister E, Gomez D, Raboni SM, Giamberardino HIG, Nunes MC, Burtseva E, Sominina A, Medić S, Coulibaly D, Salah AB, Otieno NA, Koul PA, Unal S, Tanriover MD, Mazur M, Bresee J, Viboud C, Chaves SS. Predictors of Severity of Influenza-Related Hospitalizations: Results From the Global Influenza Hospital Surveillance Network (GIHSN). J Infect Dis 2024; 229:999-1009. [PMID: 37527470 PMCID: PMC11011157 DOI: 10.1093/infdis/jiad303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Revised: 07/13/2023] [Accepted: 07/26/2023] [Indexed: 08/03/2023] Open
Abstract
BACKGROUND The Global Influenza Hospital Surveillance Network (GIHSN) has since 2012 provided patient-level data on severe influenza-like-illnesses from >100 participating clinical sites worldwide based on a core protocol and consistent case definitions. METHODS We used multivariable logistic regression to assess the risk of intensive care unit admission, mechanical ventilation, and in-hospital death among hospitalized patients with influenza and explored the role of patient-level covariates and country income level. RESULTS The data set included 73 121 patients hospitalized with respiratory illness in 22 countries, including 15 660 with laboratory-confirmed influenza. After adjusting for patient-level covariates we found a 7-fold increase in the risk of influenza-related intensive care unit admission in lower middle-income countries (LMICs), compared with high-income countries (P = .01). The risk of mechanical ventilation and in-hospital death also increased by 4-fold in LMICs, though these differences were not statistically significant. We also find that influenza mortality increased significantly with older age and number of comorbid conditions. Across all severity outcomes studied and after controlling for patient characteristics, infection with influenza A/H1N1pdm09 was more severe than with A/H3N2. CONCLUSIONS Our study provides new information on influenza severity in underresourced populations, particularly those in LMICs.
Collapse
Affiliation(s)
- Lily E Cohen
- Ready2Respond p/o The Task Force for Global Health, Decatur, Georgia, USA
- Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Chelsea L Hansen
- Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, USA
- Brotman Baty Institute, University of Washington, Seattle, Washington, USA
- PandemiX Center, Department of Science & Environment, Roskilde University, Denmark
| | - Melissa K Andrew
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Shelly A McNeil
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | - Jan Kyncl
- Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czech Republic
- Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Javier Díez Domingo
- Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO–Public Health), Valencia, Spain
| | - Tao Zhang
- School of Public Health, Fudan University, Shanghai, China
| | - Ghassan Dbaibo
- Center for Infectious Diseases Research, American University of Beirut, Beirut, Lebanon
| | | | - Anca Draganescu
- National Institute for Infectious Diseases “Prof Dr Matei Bals”, Bucharest, Romania
| | - Elsa Baumeister
- Respiratory Virus Laboratory, Virology Department, INEI-ANLIS, Buenos Aires, Argentina
| | - Doris Gomez
- Grupo de Investigación UNIMOL, Facultad de Medicina, Universidad de Cartagena, Cartagena de Indias, Colombia
| | - Sonia M Raboni
- Virology Laboratory, Infectious Diseases Division, Universidade Federal do Paraná, Hospital Pequeno Principe, Curitiba, Paraná, Brazil
| | - Heloisa I G Giamberardino
- Virology Laboratory, Infectious Diseases Division, Universidade Federal do Paraná, Hospital Pequeno Principe, Curitiba, Paraná, Brazil
| | - Marta C Nunes
- South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Elena Burtseva
- Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russian Federation, Moscow, Russia
| | - Anna Sominina
- Smorodintsev Research Institute of Influenza, St Petersburg, Russia
| | - Snežana Medić
- Institute for Public Health of Vojvodina, Novi Sad, Serbia
- Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
| | | | - Afif Ben Salah
- Institut Pasteur de Tunis, Tunis, Tunisia
- Arabian Gulf University, Manama, Bahrain
| | - Nancy A Otieno
- Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
| | - Parvaiz A Koul
- Sheri Kashmir Institute of Medical Sciences, Srinagar, India
| | - Serhat Unal
- Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey
- Turkish Society of Internal Medicine, Ankara, Turkey
| | - Mine Durusu Tanriover
- Turkish Society of Internal Medicine, Ankara, Turkey
- Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
| | - Marie Mazur
- Ready2Respond p/o The Task Force for Global Health, Decatur, Georgia, USA
| | - Joseph Bresee
- Ready2Respond p/o The Task Force for Global Health, Decatur, Georgia, USA
| | - Cecile Viboud
- Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Sandra S Chaves
- Foundation for Influenza Epidemiology, Fondation de France, Paris, France
| |
Collapse
|
2
|
Krivitskaya V, Petrova E, Sorokin E, Tsareva T, Sverlova M, Komissarova K, Sominina A, Danilenko D. Characterization of a Panel of Monoclonal Antibodies Targeting the F-Protein of the Respiratory Syncytial Virus (RSV) for the Typing of Contemporary Circulating Strains. Trop Med Infect Dis 2023; 9:1. [PMID: 38276631 PMCID: PMC10819491 DOI: 10.3390/tropicalmed9010001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 12/01/2023] [Accepted: 12/06/2023] [Indexed: 01/27/2024] Open
Abstract
Respiratory syncytial virus (RSV) is the most common cause of upper and lower respiratory tract infections in infants and young children. Virus-specific monoclonal antibodies (mAbs) can be used for diagnosis, prophylaxis, and research of RSV pathogenesis. A panel of 16 anti-RSV mAbs was obtained from mice immunized by RSV strain Long. Half of them had virus-neutralizing activity. According to Western blot all of these mAbs effectively bound native oligomeric (homodimeric and homotrimeric) forms of the RSV fusion (F) protein. Only five of the mAbs interacted with the monomeric form, and only one of these possessed neutralizing activity. None of these mAbs, nor the commercial humanized neutralizing mAb palivizumab, reacted with the denaturated F protein. Thus, interaction of all these mAbs with F protein had clear conformational dependence. Competitive ELISA and neutralization assays allowed the identification of nine antigenic target sites for the interaction of mAb with the F protein. Five partially overlapping sites may represent a complex spatial structure of one antigenic determinant, including one neutralizing and four non-neutralizing epitopes. Four sites (three neutralizing and one non-neutralizing) were found to be distinct. As a result of virus cultivation RSV-A, strain Long, in the presence of a large amount of one of the neutralizing mAbs, an escape mutant with a substitution, N240S, in the F protein, was obtained. Thus, it was shown for the first time that position 240 is critical for the protective effect of an anti-RSV antibody. To assess the ability of these mAbs to interact with modern RSV strains circulating in St. Petersburg (Russia) between 2014 and 2022, 73 RSV-A and 22 RSV-B isolates were analyzed. Six mAbs were directed to conserved epitopes of the F protein as they interacted most efficiently with both RSV subtypes in a fixed cell-ELISA and could be used for diagnostic assays detecting RSV.
Collapse
Affiliation(s)
- Vera Krivitskaya
- Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, WHO National Influenza Centre, St. Petersburg 197376, Russia; (E.P.); (E.S.); (T.T.); (M.S.); (K.K.); (A.S.); (D.D.)
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Sominina A, Danilenko D, Komissarov AB, Pisareva M, Fadeev A, Konovalova N, Eropkin M, Petrova P, Zheltukhina A, Musaeva T, Eder V, Ivanova A, Komissarova K, Stolyarov K, Karpova L, Smorodintseva E, Dorosh A, Krivitskaya V, Kuznetzova E, Majorova V, Petrova E, Boyarintseva A, Ksenafontov A, Shtro A, Nikolaeva J, Bakaev M, Burtseva E, Lioznov D. Assessing the Intense Influenza A(H1N1)pdm09 Epidemic and Vaccine Effectiveness in the Post-COVID Season in the Russian Federation. Viruses 2023; 15:1780. [PMID: 37632122 PMCID: PMC10458445 DOI: 10.3390/v15081780] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 07/31/2023] [Accepted: 08/16/2023] [Indexed: 08/27/2023] Open
Abstract
The COVID-19 pandemic had a profound impact on influenza activity worldwide. However, as the pandemic progressed, influenza activity resumed. Here, we describe the influenza epidemic of high intensity of the 2022-2023 season. The epidemic had an early start and peaked in week 51.2022. The extremely high intensity of the epidemic may have been due to a significant decrease in herd immunity. The results of PCR-testing of 220,067 clinical samples revealed that the influenza A(H1N1)pdm09 virus dominated, causing 56.4% of positive cases, while A(H3N2) influenza subtype accounted for only 0.6%, and influenza B of Victoria lineage-for 34.3%. The influenza vaccine was found to be highly effective, with an estimated effectiveness of 92.7% in preventing admission with laboratory-confirmed influenza severe acute respiratory illness (SARI) cases and 54.7% in preventing influenza-like illness/acute respiratory illness (ILI/ARI) cases due to antigenic matching of circulated viruses with influenza vaccine strains for the season. Full genome next-generation sequencing of 1723 influenza A(H1N1)pdm09 viruses showed that all of them fell within clade 6B.1A.5.a2; nine of them possessed H275Y substitution in the NA gene, a genetic marker of oseltamivir resistance. Influenza A(H3N2) viruses belonged to subclade 3C.2a1b.2a.2 with the genetic group 2b being dominant. All 433 influenza B viruses belonged to subclade V1A.3a.2 encoding HA1 substitutions A127T, P144L, and K203R, which could be further divided into two subgroups. None of the influenza A(H3N2) and B viruses sequenced had markers of resistance to NA inhibitors. Thus, despite the continuing circulation of Omicron descendant lineages, influenza activity has resumed in full force, raising concerns about the intensity of fore coming seasonal epidemics.
Collapse
Affiliation(s)
- Anna Sominina
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Daria Danilenko
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Andrey B. Komissarov
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Maria Pisareva
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Artem Fadeev
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Nadezhda Konovalova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Mikhail Eropkin
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Polina Petrova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Alyona Zheltukhina
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Tamila Musaeva
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Veronika Eder
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Anna Ivanova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Kseniya Komissarova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Kirill Stolyarov
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Ludmila Karpova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Elizaveta Smorodintseva
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Anna Dorosh
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Vera Krivitskaya
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Elena Kuznetzova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Victoria Majorova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Ekaterina Petrova
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Anastassia Boyarintseva
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Andrey Ksenafontov
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Anna Shtro
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Julia Nikolaeva
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Mikhail Bakaev
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
| | - Elena Burtseva
- National Research Center for Epidemiology and Microbiology Named after N.F. Gamaleya, 123098 Moscow, Russia
| | - Dmitry Lioznov
- Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia; (D.D.); (E.K.)
- Department of Infectious Diseases, First Pavlov State Medical University, 197022 Saint Petersburg, Russia
| |
Collapse
|
4
|
Andrew MK, Pott H, Staadegaard L, Paget J, Chaves SS, Ortiz JR, McCauley J, Bresee J, Nunes MC, Baumeister E, Raboni SM, Giamberardino HIG, McNeil SA, Gomez D, Zhang T, Vanhems P, Koul PA, Coulibaly D, Otieno NA, Dbaibo G, Almeida MLG, Laguna-Torres VA, Drăgănescu AC, Burtseva E, Sominina A, Danilenko D, Medić S, Diez-Domingo J, Lina B. Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network. Open Forum Infect Dis 2023; 10:ofad244. [PMID: 37383245 PMCID: PMC10296081 DOI: 10.1093/ofid/ofad244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 04/26/2023] [Indexed: 06/30/2023] Open
Abstract
Background The Global Influenza Hospital Surveillance Network (GIHSN) was established in 2012 to conduct coordinated worldwide influenza surveillance. In this study, we describe underlying comorbidities, symptoms, and outcomes in patients hospitalized with influenza. Methods Between November 2018 and October 2019, GIHSN included 19 sites in 18 countries using a standardized surveillance protocol. Influenza infection was laboratory-confirmed with reverse-transcription polymerase chain reaction. A multivariate logistic regression model was utilized to analyze the extent to which various risk factors predict severe outcomes. Results Of 16 022 enrolled patients, 21.9% had laboratory-confirmed influenza; 49.2% of influenza cases were A/H1N1pdm09. Fever and cough were the most common symptoms, although they decreased with age (P < .001). Shortness of breath was uncommon among those <50 years but increased with age (P < .001). Middle and older age and history of underlying diabetes or chronic obstructive pulmonary disease were associated with increased odds of death and intensive care unit (ICU) admission, and male sex and influenza vaccination were associated with lower odds. The ICU admissions and mortality occurred across the age spectrum. Conclusions Both virus and host factors contributed to influenza burden. We identified age differences in comorbidities, presenting symptoms, and adverse clinical outcomes among those hospitalized with influenza and benefit from influenza vaccination in protecting against adverse clinical outcomes. The GIHSN provides an ongoing platform for global understanding of hospitalized influenza illness.
Collapse
Affiliation(s)
- Melissa K Andrew
- Correspondence: Melissa K. Andrew, MD, PhD, Department of Medicine (Geriatrics), Dalhousie University, 5955 Veterans Memorial Lane, Halifax, NS B3H 2E1, Canada (); Bruno Lina, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon, 69317 CEDEX 04, France ()
| | - Henrique Pott
- Dalhousie University and Canadian Center for Vaccinology, Halifax, Canada
- Department of Medicine, Universidade Federal de São Carlos, São Carlos, Brazil
| | - Lisa Staadegaard
- Netherlands Institute for Health Care Research (Nivel), Utrecht, Netherlands
| | - John Paget
- Netherlands Institute for Health Care Research (Nivel), Utrecht, Netherlands
| | - Sandra S Chaves
- Foundation for Influenza Epidemiology, Fondation de France, Paris, France
| | - Justin R Ortiz
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
| | - John McCauley
- WHO Collaborating Centre for Reference and Research on Influenza, Crick Institute, London, United Kingdom
| | - Joseph Bresee
- Centre for Vaccine Equity, Task Force for Global Health, Atlanta, Georgia, USA
| | - Marta C Nunes
- South African Medical Research Council, Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, and Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences University of the Witwatersrand, Johannesburg, South Africa
| | - Elsa Baumeister
- National Reference Laboratory for Viral Respiratory Diseases, Virology Department, INEI-ANLIS, Buenos Aires, Argentina
| | - Sonia Mara Raboni
- Molecular Biology/Microbiology Research Laboratory, Universidade Federal do Paraná, Curitiba, Brazil
| | - Heloisa I G Giamberardino
- Epidemiology, Immunization and Infection Control Department—Hospital Pequeno Principe, Curitiba, Paraná, Brazil
| | - Shelly A McNeil
- Dalhousie University and Canadian Center for Vaccinology, Halifax, Canada
| | - Doris Gomez
- Grupo de Investigación UNIMOL, Facultad de Medicina, Universidad de Cartagena, Cartagena de Indias, Colombia
| | - Tao Zhang
- School of Public Health, Fudan University, Shanghai, China
| | | | | | - Daouda Coulibaly
- Institut National d'Hygiène Publique (INHP), Abidjan, Côte d’Ivoire
| | - Nancy A Otieno
- Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
| | - Ghassan Dbaibo
- Center for Infectious Diseases Research, American University of Beirut, Beirut, Lebanon
| | | | | | | | - Elena Burtseva
- FSBI “N.F. Gamaleya NRCEM” Ministry of Health of the Russian Federation (Federal Research Budgetary Institute “National Research Center of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya), Moscow, Russia
| | - Anna Sominina
- Smorodintsev Research Institute of Influenza, St. Petersburg, Russia
| | - Daria Danilenko
- Smorodintsev Research Institute of Influenza, St. Petersburg, Russia
| | - Snežana Medić
- Institute of Public Health of Vojvodina, Novi Sad, Serbia
- Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
| | | | - Bruno Lina
- Correspondence: Melissa K. Andrew, MD, PhD, Department of Medicine (Geriatrics), Dalhousie University, 5955 Veterans Memorial Lane, Halifax, NS B3H 2E1, Canada (); Bruno Lina, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon, 69317 CEDEX 04, France ()
| |
Collapse
|
5
|
Caini S, Stolyarov K, Sominina A, Smorodintseva E, Staadegaard L, Paget J, Danilenko D. A comparative analysis of the epidemiology of influenza and respiratory syncytial virus in Russia, 2013/14 to 2018/19. J Glob Health 2022; 12:04009. [PMID: 35136600 PMCID: PMC8818296 DOI: 10.7189/jogh.12.04009] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background Influenza and respiratory syncytial virus (RSV) are among the leading causes of lower respiratory tract infections worldwide. We conducted a comparative analysis of the age distribution and spatiotemporal epidemiology of influenza and RSV in Russia using sentinel surveillance data from 2013-14 to 2018-19 in six cities located in the western, central, and eastern regions of the country. Methods We calculated the positivity rate for influenza and RSV (by month, season, and overall) in each city, separately for patients seen at the primary and secondary care level (out-patients medical centres housing GP practices and infectious diseases hospitals, respectively). We compared the age distribution of patients infected with the different influenza virus (sub)types and RSV. Results A total of 17 551 respiratory specimens were included: the overall positivity rate was 13.5% for influenza and 4.4% for RSV. The A(H1N1)pdm09, A(H3N2) and B virus (sub)types caused 31.3%, 44.0% and, respectively, 24.7% of all influenza cases. The median age was older among influenza (15 years) than among RSV patients (3 years); differences across influenza virus (sub)types were seen only at the primary care level, with influenza A(H3N2) patients being significantly older than A(H1N1)pdm09 or B influenza patients. The timing of influenza epidemics was similar across cities, with the peak typically occurring in February or March. In contrast, the typical peak timing of RSV epidemics varied largely across cities, and the virus was often detected also in spring and summer months (unlike influenza). Conclusions Influenza and RSV epidemiology differed in many regards in Russia, especially in the timing of epidemics and the age distribution of infected subjects. Health policies aimed at containing the burden of diseases of viral respiratory infections in Russia should take these findings into account.
Collapse
Affiliation(s)
- Saverio Caini
- Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands
| | - Kirill Stolyarov
- Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia
| | - Anna Sominina
- Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia
| | | | - Lisa Staadegaard
- Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands
| | - John Paget
- Netherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands
| | - Daria Danilenko
- Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia
| |
Collapse
|
6
|
Krivitskaya V, Komissarova K, Pisareva M, Sverlova M, Fadeev A, Petrova E, Timonina V, Sominina A, Danilenko D. Respiratory Syncytial Virus G Protein Sequence Variability among Isolates from St. Petersburg, Russia, during the 2013-2014 Epidemic Season. Viruses 2021; 13:119. [PMID: 33477301 PMCID: PMC7830914 DOI: 10.3390/v13010119] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 01/10/2021] [Accepted: 01/12/2021] [Indexed: 11/16/2022] Open
Abstract
Human respiratory syncytial virus (RSV) is the most common cause of upper and lower respiratory tract infections in infants and young children. It is actively evolving under environmental and herd immunity influences. This work presents, for the first time, sequence variability analysis of RSV G gene and G protein using St. Petersburg (Russia) isolates. Viruses were isolated in a cell culture from the clinical samples of 61 children hospitalized (January-April 2014) with laboratory-confirmed RSV infection. Real-time RT-PCR data showed that 56 isolates (91.8%) belonged to RSV-A and 5 isolates (8.2%) belonged to RSV-B. The G genes were sequenced for 27 RSV-A isolates and all of them belonged to genotype ON1/GA2. Of these RSV-A, 77.8% belonged to the ON1(1.1) genetic sub-cluster, and 14.8% belonged to the ON1(1.2) sub-cluster. The ON1(1.3) sub-cluster constituted a minor group (3.7%). Many single-amino acid substitutions were identified in the G proteins of St. Petersburg isolates, compared with the Canadian ON1/GA2 reference virus (ON67-1210A). Most of the amino acid replacements were found in immunodominant B- and T-cell antigenic determinants of G protein. These may affect the antigenic characteristics of RSV and influence the host antiviral immune response to currently circulating viruses.
Collapse
Affiliation(s)
- Vera Krivitskaya
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Kseniya Komissarova
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Maria Pisareva
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Maria Sverlova
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Artem Fadeev
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Ekaterina Petrova
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Veronika Timonina
- Children’s City Hospital of St. Olga, 194017 Saint-Petersburg, Russia;
| | - Anna Sominina
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| | - Daria Danilenko
- Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (V.K.); (M.P.); (M.S.); (A.F.); (E.P.); (A.S.); (D.D.)
| |
Collapse
|
7
|
Puig-Barberà J, Mira-Iglesias A, Burtseva E, Cowling BJ, Serhat U, Ruiz-Palacios GM, Launay O, Kyncl J, Koul P, Siqueira MM, Sominina A. Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance Network. BMC Infect Dis 2019; 19:415. [PMID: 31088481 PMCID: PMC6518734 DOI: 10.1186/s12879-019-4017-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 04/24/2019] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND The Global Influenza Hospital Surveillance Network is an international platform whose primary objective is to study severe cases of influenza requiring hospitalization. METHODS During the 2015-2016 influenza season, 11 sites in the Global Influenza Hospital Surveillance Network in nine countries (Russian Federation, Czech Republic, Turkey, France, China, Spain, Mexico, India, and Brazil) participated in a prospective, active-surveillance, hospital-based epidemiological study. Influenza infection was confirmed by reverse transcription-polymerase chain reaction. Influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza was estimated using a test-negative approach. RESULTS 9882 patients with laboratory results were included of which 2415 (24.4%) were positive for influenza, including 1415 (14.3%) for A(H1N1)pdm09, 235 (2.4%) for A(H3N2), 180 (1.8%) for A not subtyped, 45 (0.5%) for B/Yamagata-lineage, 532 (5.4%) for B/Victoria-lineage, and 33 (0.3%) for B not subtyped. Of included admissions, 39% were < 5 years of age and 67% had no underlying conditions. The odds of being admitted with influenza were higher among pregnant than non-pregnant women (odds ratio, 2.82 [95% confidence interval (CI), 1.90 to 4.19]). Adjusted IVE against influenza-related hospitalization was 16.3% (95% CI, 0.4 to 29.7). Among patients targeted for influenza vaccination, adjusted IVE against hospital admission with influenza was 16.2% (95% CI, - 3.6 to 32.2) overall, 23.0% (95% CI, - 3.3 to 42.6) against A(H1N1)pdm09, and - 25.6% (95% CI, - 86.3 to 15.4) against B/Victoria lineage. CONCLUSIONS The 2015-2016 influenza season was dominated by A(H1N1)pdm09 and B/Victoria-lineage. Hospitalization with influenza often occurred in healthy and young individuals, and pregnant women were at increased risk of influenza-related hospitalization. Influenza vaccines provided low to moderate protection against hospitalization with influenza and no protection against the predominant circulating B lineage, highlighting the need for more effective and broader influenza vaccines.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO, Valencia, Spain.
| | - Ainara Mira-Iglesias
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, FISABIO, Valencia, Spain
| | - Elena Burtseva
- Ivanovsky Institute of Virology FSBI "N.F, Gamaleya NRCEM" Ministry of Health, Moscow, Russian Federation
| | - Benjamin J Cowling
- School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong, Special Administrative Region of China
| | - Unal Serhat
- Turkish Society of Internal Medicine, Ankara, Turkey
| | - Guillermo Miguel Ruiz-Palacios
- Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ), Vasco de Quiroga 15, Belisario Domínguez Sección 16, 14080, Tlalpan, CDMX, Mexico
| | - Odile Launay
- INSERM, F-CRIN, Réseau National d'Investigation Clinique en Vaccinologie (I-REIVAC), CIC Cochin Pasteur, Paris, France and Université Paris Descartes, Sorbonne Paris Cité and Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Jan Kyncl
- National Institute of Public Health, Prague, Czech Republic
| | - Parvaiz Koul
- Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, Bemina, Srinagar, Jammu & Kashmir, 190011, India
| | | | - Anna Sominina
- Research Institute of Influenza, WHO National Influenza Centre of Russia and Ministry of Healthcare of the Russian Federation, St. Petersburg, Russian Federation
| | | |
Collapse
|
8
|
Baselga-Moreno V, Trushakova S, McNeil S, Sominina A, Nunes MC, Draganescu A, Unal S, Koul P, Kyncl J, Zhang T, Kuatbayeva A, Ben-Salah A, Burtseva E, Puig-Barberà J, Díez-Domingo J. Influenza epidemiology and influenza vaccine effectiveness during the 2016-2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health 2019; 19:487. [PMID: 31046725 PMCID: PMC6498567 DOI: 10.1186/s12889-019-6713-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 03/27/2019] [Indexed: 11/25/2022] Open
Abstract
Background The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season. Methods A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. Results Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women. Conclusions Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn’t allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women. Electronic supplementary material The online version of this article (10.1186/s12889-019-6713-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Víctor Baselga-Moreno
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain
| | - Svetlana Trushakova
- Ivanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation
| | - Shelly McNeil
- Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Halifax, Canada
| | - Anna Sominina
- Research Institute of Influenza, WHO National Influenza Centre of Russia, St. Petersburg, Russian Federation
| | - Marta C Nunes
- Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.,Department of Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa
| | - Anca Draganescu
- National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest (INBI "Prof. Dr. Matei Bals"), București, Romania
| | - Serhat Unal
- Turkish Society of Internal Medicine, Ankara, Turkey
| | - Parvaiz Koul
- Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, India
| | - Jan Kyncl
- National Institute of Public Health, Prague, Czech Republic
| | | | - Ainagul Kuatbayeva
- Center for Sanitary-Epidemiological Expertise and Monitoring, Almaty, Kazakhstan
| | - Afif Ben-Salah
- Pasteur Institute of Tunis, Tunis, Tunisia.,College of Medicine and Medical Sciences, Manama, Bahrain
| | - Elena Burtseva
- Ivanovsky Institute of Virology FSBI "N.F. Gamaleya FRCEM" Ministry of Health, Moscow, Russian Federation
| | - Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain
| | - Javier Díez-Domingo
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 21 Cataluña Av, 46020, Valencia, Spain.
| | | |
Collapse
|
9
|
López-Labrador FX, Natividad-Sancho A, Pisareva M, Komissarov A, Salvatierra K, Fadeev A, Moya A, Grudinin M, Díez-Domingo J, Afanasieva O, Konovalova N, Sominina A, Puig-Barberà J. Genetic characterization of influenza viruses from influenza-related hospital admissions in the St. Petersburg and Valencia sites of the Global Influenza Hospital Surveillance Network during the 2013/14 influenza season. J Clin Virol 2016; 84:32-38. [PMID: 27690141 DOI: 10.1016/j.jcv.2016.09.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 09/06/2016] [Accepted: 09/19/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND Continuous surveillance for genetic changes in circulating influenza viruses is needed to guide influenza prevention and control. OBJECTIVES To compare intra-seasonal influenza genetic diversity of hemagglutinin in influenza A strains isolated from influenza hospital admissions collected at two distinct sites during the same season. STUDY DESIGN Comparative phylogenetic analysis of full-length hemagglutinin genes from 77 isolated influenza A viruses from the St. Petersburg, Russian Federation and Valencia, Spain sites of the Global Influenza Hospital Surveillance Network (GIHSN) during the 2013/14 season. RESULTS We found significant variability in A(H3N2) and A(H1N1)pdm09 viruses between the two sites, with nucleotide variation at antigenic positions much lower for A(H1N1)pdm09 than for A(H3N2) viruses. For A(H1N1)pdm09, antigenic sites differed by three to four amino acids from the vaccine strain, two of them common to all tested isolates. For A(H3N2) viruses, antigenic sites differed by six to nine amino acids from the vaccine strain, four of them common to all tested isolates. A fifth amino acid substitution in the antigenic sites of A(H3N2) defined a new clade, 3C.2. For both influenza A subtypes, pairwise amino acid distances between circulating viruses and vaccine strains were significantly higher at antigenic than at non-antigenic sites. Whereas A(H1N1)pdm09 viruses clustered with clade 6B and 94% of A(H3N2) with clade 3C.3, at both study sites A(H3N2) clade 3C.2 viruses emerged towards the end of the season, showing greater pairwise amino acid distances from the vaccine strain compared to the predominant clade 3C.3. CONCLUSIONS Influenza A antigenic variants differed between St. Petersburg and Valencia, and A(H3N2) clade 3C.2 viruses were characterized by more amino acid differences from the vaccine strain, especially at the antigenic sites.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- Child, Preschool
- Epidemiological Monitoring
- Female
- Genetic Variation
- Genome, Viral
- Global Health
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Humans
- Infant
- Influenza A Virus, H1N1 Subtype/genetics
- Influenza A Virus, H1N1 Subtype/isolation & purification
- Influenza A Virus, H3N2 Subtype/genetics
- Influenza A Virus, H3N2 Subtype/isolation & purification
- Influenza, Human/epidemiology
- Influenza, Human/virology
- Male
- Middle Aged
- Phylogeny
- RNA, Viral/genetics
- Russia/epidemiology
- Seasons
- Sequence Analysis, DNA
- Spain/epidemiology
- Young Adult
Collapse
Affiliation(s)
- F Xavier López-Labrador
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain; Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Publica (CIBER-ESP), Instituto de Salud Carlos III, Spain.
| | - Angels Natividad-Sancho
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| | - Maria Pisareva
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Andrey Komissarov
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Karina Salvatierra
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain; Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain.
| | - Artem Fadeev
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Andrés Moya
- Joint Units of Infection and of Genomics and Health, FISABIO/Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, Spain.
| | - Mikhail Grudinin
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Javier Díez-Domingo
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| | - Olga Afanasieva
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Nadezhda Konovalova
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Anna Sominina
- Research Institute of Influenza, Ministry of Health, Prof. Popov Str. 15/17, St. Petersburg, Russian Federation.
| | - Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Avda. de Catalunya, 21, 46020 Valencia, Spain.
| |
Collapse
|
10
|
Puig-Barberà J, Burtseva E, Yu H, Cowling BJ, Badur S, Kyncl J, Sominina A. Influenza epidemiology and influenza vaccine effectiveness during the 2014-2015 season: annual report from the Global Influenza Hospital Surveillance Network. BMC Public Health 2016; 16 Suppl 1:757. [PMID: 27556802 PMCID: PMC5001209 DOI: 10.1186/s12889-016-3378-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The Global Influenza Hospital Surveillance Network (GIHSN) has established a prospective, active surveillance, hospital-based epidemiological study to collect epidemiological and virological data for the Northern and Southern Hemispheres over several consecutive seasons. It focuses exclusively on severe cases of influenza requiring hospitalization. A standard protocol is shared between sites allowing comparison and pooling of results. During the 2014-2015 influenza season, the GIHSN included seven coordinating sites from six countries (St. Petersburg and Moscow, Russian Federation; Prague, Czech Republic; Istanbul, Turkey; Beijing, China; Valencia, Spain; and Rio de Janeiro, Brazil). Here, we present the detailed epidemiological and influenza vaccine effectiveness findings for the Northern Hemisphere 2014-2015 influenza season.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO - Public Health, Avda Catalunya 21, 46020, Valencia, Spain.
| | - Elena Burtseva
- D.I. Ivanovsky Institute of Virology FGBC "N.F. Gamaleya FRCEM" Ministry of Health of Russian Federation, Moscow, Russian Federation, Russia
| | - Hongjie Yu
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Benjamin J Cowling
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China
| | - Selim Badur
- National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Jan Kyncl
- National Institute of Public Health (NIPH), Prague, Czech Republic
| | - Anna Sominina
- Research Institute of Influenza, Saint Petersburg, Russian Federation, Russia
| | | |
Collapse
|
11
|
Komissarov A, Fadeev A, Sergeeva M, Petrov S, Sintsova K, Egorova A, Pisareva M, Buzitskaya Z, Musaeva T, Danilenko D, Konovalova N, Petrova P, Stolyarov K, Smorodintseva E, Burtseva E, Krasnoslobodtsev K, Kirillova E, Karpova L, Eropkin M, Sominina A, Grudinin M. Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation). Influenza Other Respir Viruses 2016; 10:247-53. [PMID: 26992820 PMCID: PMC4910175 DOI: 10.1111/irv.12389] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2016] [Indexed: 12/14/2022] Open
Abstract
A dramatic increase of influenza activity in Russia since week 3 of 2016 significantly differs from previous seasons in terms of the incidence of influenza and acute respiratory infection (ARI) and in number of lethal cases. We performed antigenic analysis of 108 and whole-genome sequencing of 77 influenza A(H1N1)pdm09 viruses from Moscow and Saint Petersburg. Most of the viruses were antigenically related to the vaccine strain. Whole-genome analysis revealed a composition of specific mutations in the internal genes (D2E and M83I in NEP, E125D in NS1, M105T in NP, Q208K in M1, and N204S in PA-X) that probably emerged before the beginning of 2015/2016 epidemic season.
Collapse
Affiliation(s)
- Andrey Komissarov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Artem Fadeev
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Maria Sergeeva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Influenza Vaccines, Saint Petersburg, Russia
| | - Sergey Petrov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Influenza Vaccines, Saint Petersburg, Russia
| | - Kseniya Sintsova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Anna Egorova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Maria Pisareva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Zhanna Buzitskaya
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Tamila Musaeva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, Saint Petersburg, Russia
| | - Daria Danilenko
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Nadezhda Konovalova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Polina Petrova
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Kirill Stolyarov
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Department of IT, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Elizaveta Smorodintseva
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Biotechnology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Elena Burtseva
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Kirill Krasnoslobodtsev
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Elena Kirillova
- Federal Research Center of Epidemiology and Microbiology named after N. F. Gamaleya, WHO-recognized National Influenza Centre of Russian Federation, Moscow, Russia
| | - Lyudmila Karpova
- Research Institute of Influenza, Laboratory of Influenza and ARI Epidemiology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Mikhail Eropkin
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Evolutionary Variability of Influenza Viruses, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Anna Sominina
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Biotechnology, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| | - Mikhail Grudinin
- Research Institute of Influenza, Ministry of Healthcare of the Russian Federation, Laboratory of Molecular Virology and Genetic Engineering, WHO-recognized National Influenza Centre of Russian Federation, Saint Petersburg, Russia
| |
Collapse
|
12
|
Puig-Barberà J, Natividad-Sancho A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, Badur S, Yu H, Cowling BJ, El Guerche-Séblain C, Mira-Iglesias A, Kisteneva L, Stolyarov K, Yurtcu K, Feng L, López-Labrador X, Burtseva E. Epidemiology of Hospital Admissions with Influenza during the 2013/2014 Northern Hemisphere Influenza Season: Results from the Global Influenza Hospital Surveillance Network. PLoS One 2016; 11:e0154970. [PMID: 27196667 PMCID: PMC4873033 DOI: 10.1371/journal.pone.0154970] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 04/21/2016] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The Global Influenza Hospital Surveillance Network was established in 2012 to obtain valid epidemiologic data on hospital admissions with influenza-like illness. Here we describe the epidemiology of admissions with influenza within the Northern Hemisphere sites during the 2013/2014 influenza season, identify risk factors for severe outcomes and complications, and assess the impact of different influenza viruses on clinically relevant outcomes in at-risk populations. METHODS Eligible consecutive admissions were screened for inclusion at 19 hospitals in Russia, Turkey, China, and Spain using a prospective, active surveillance approach. Patients that fulfilled a common case definition were enrolled and epidemiological data were collected. Risk factors for hospitalization with laboratory-confirmed influenza were identified by multivariable logistic regression. FINDINGS 5303 of 9507 consecutive admissions were included in the analysis. Of these, 1086 were influenza positive (534 A(H3N2), 362 A(H1N1), 130 B/Yamagata lineage, 3 B/Victoria lineage, 40 untyped A, and 18 untyped B). The risk of hospitalization with influenza (adjusted odds ratio [95% confidence interval]) was elevated for patients with cardiovascular disease (1.63 [1.33-2.02]), asthma (2.25 [1.67-3.03]), immunosuppression (2.25 [1.23-4.11]), renal disease (2.11 [1.48-3.01]), liver disease (1.94 [1.18-3.19], autoimmune disease (2.97 [1.58-5.59]), and pregnancy (3.84 [2.48-5.94]). Patients without comorbidities accounted for 60% of admissions with influenza. The need for intensive care or in-hospital death was not significantly different between patients with or without influenza. Influenza vaccination was associated with a lower risk of confirmed influenza (adjusted odds ratio = 0.61 [0.48-0.77]). CONCLUSIONS Influenza infection was detected among hospital admissions with and without known risk factors. Pregnancy and underlying comorbidity increased the risk of detecting influenza virus in patients hospitalized with influenza-like illness. Our results support influenza vaccination as a measure for reducing the risk of influenza-associated hospital admission.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain
- * E-mail:
| | - Angels Natividad-Sancho
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain
| | - Svetlana Trushakova
- D.I. Ivanovsky Institute of Virology FSBI “N.F. Gamaleya FRCEM” Ministry of Health of Russian Federation, Moscow, Russian Federation
| | - Anna Sominina
- Research Institute of Influenza, St. Petersburg, Russian Federation
| | - Maria Pisareva
- Research Institute of Influenza, St. Petersburg, Russian Federation
| | - Meral A. Ciblak
- National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Selim Badur
- National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Hongjie Yu
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Benjamin J. Cowling
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
| | | | - Ainara Mira-Iglesias
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain
| | - Lidiya Kisteneva
- D.I. Ivanovsky Institute of Virology FSBI “N.F. Gamaleya FRCEM” Ministry of Health of Russian Federation, Moscow, Russian Federation
| | - Kirill Stolyarov
- Research Institute of Influenza, St. Petersburg, Russian Federation
| | - Kubra Yurtcu
- National Influenza Reference Laboratory, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Luzhao Feng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xavier López-Labrador
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain
- Centro de Investigación Biomédica en Epidemiología y Salud Publica (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Elena Burtseva
- D.I. Ivanovsky Institute of Virology FSBI “N.F. Gamaleya FRCEM” Ministry of Health of Russian Federation, Moscow, Russian Federation
| | | |
Collapse
|
13
|
Puig-Barberà J, Natividad-Sancho A, Trushakova S, Sominina A, Smorodintseva E, Ciblak MA, Badur S, Yu H, J.Cowling B, Mira-Iglesias A, Kolobukhina L, Voloshchuk L, Yurtcu K, Wu P, Burtseva E. Vaccine Effectiveness in Preventing Hospitalizations With Influenza: Preliminary Results From the Global Influenza Hospital Surveillance Network for the Northern Hemisphere 2013/14 Influenza Season Using a Test-Negative Approach. Open Forum Infect Dis 2015. [DOI: 10.1093/ofid/ofv133.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Puig-Barberà J, Natividad-Sancho A, Trushakova S, Sominina A, Pisareva M, A.Ciblak M, Badur S, Yu H, J.Cowling B, Guerche-Séblain CE, Mira-Iglesias A, Kisteneva L, Stolyarov K, Yurtcu K, Feng L, Burtseva E. Epidemiology of Admissions With Influenza and the Impact of Underlying Patient Characteristics on the Risk of Admission With Influenza During the 2013/14 Season in the GIHSN Participating Sites. Open Forum Infect Dis 2015. [DOI: 10.1093/ofid/ofv133.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Puig-Barberà J, Tormos A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, Badur S, Yu H, Cowling BJ, Burtseva E. The Global Influenza Hospital Surveillance Network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respir Viruses 2015; 9:277-286. [PMID: 26198771 PMCID: PMC4605407 DOI: 10.1111/irv.12335] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2015] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Influenza is a global public health problem. However, severe influenza only recently has been addressed in routine surveillance. OBJECTIVES The Global Influenza Hospital Surveillance Network (GIHSN) was established to study the epidemiology of severe influenza in consecutive seasons in different countries. Our objective is to describe the GIHSN approach and methods. METHODS The GIHSN uses prospective active surveillance to identify consecutive influenza admissions in permanent residents of well-defined geographic areas in sites around the world. A core common protocol is followed. After consent, data are collected on patient characteristics and clinical outcomes, respiratory swabs are obtained, and the presence of influenza virus and subtype or lineage is ascertained by polymerase chain reaction. Data are collated and analyzed at the GIHSN coordination center. RESULTS The GIHSN has run its activities for two consecutive influenza seasons, 2012-2013 and 2013-2014, and hospitals in Brazil, China, France, Russian Federation, Turkey, and Spain have been involved in one or both seasons. Consistency on the application of the protocol and heterogeneity for the first season have been addressed in two previous publications. During both seasons, 19 677 eligible admissions were recorded; 11 843 (60%) were included and tested, and 2713 (23%) were positive for influenza: 991 (37%) A(H1N1); 807 (30%) A(H3N2); 583 (21%) B/Yamagata; 56 (2%) B/Victoria and 151 (6%) influenza A; and 125 (5%) influenza B were not characterized. CONCLUSIONS The GIHSN is a platform that provides information on severe influenza worldwide, applying a common core protocol and a consistent case definition.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)Valencia, Spain
| | - Anita Tormos
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)Valencia, Spain
| | | | - Anna Sominina
- Research Institute of InfluenzaSt. Petersburg, Russian Federation
| | - Maria Pisareva
- Research Institute of InfluenzaSt. Petersburg, Russian Federation
| | - Meral A Ciblak
- National Influenza Reference Laboratory Capa-IstanbulIstanbul, Turkey
| | - Selim Badur
- National Influenza Reference Laboratory Capa-IstanbulIstanbul, Turkey
| | - Hongjie Yu
- Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and PreventionBeijing, China
| | - Benjamin J Cowling
- Li Ka Shing Faculty of Medicine, School of Public Health, The University of Hong KongHong Kong, China
| | - Elena Burtseva
- D.I. Ivanovsky Institute of VirologyMoscow, Russian Federation
| | - on behalf of the GIHSN Group*
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)Valencia, Spain
- D.I. Ivanovsky Institute of VirologyMoscow, Russian Federation
- Research Institute of InfluenzaSt. Petersburg, Russian Federation
- National Influenza Reference Laboratory Capa-IstanbulIstanbul, Turkey
- Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and PreventionBeijing, China
- Li Ka Shing Faculty of Medicine, School of Public Health, The University of Hong KongHong Kong, China
| |
Collapse
|
16
|
Sorokin E, Tsareva T, Sominina A, Pisareva M, Komissarov A, Kosheleva A. Effect of single amino acid substitutions in the hemagglutinin on the receptor-binding properties of influenza B viruses. J Clin Virol 2015. [DOI: 10.1016/j.jcv.2015.07.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Eropkin M, Karpova L, Konovalova N, Lobova T, Petrova P, Eropkina E, Schekanova S, Sominina A. Influenza in Russia in the season 2014–2015: Epidemiology and antigenic properties of viruses. J Clin Virol 2015. [DOI: 10.1016/j.jcv.2015.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Smorodintseva E, Sominina A, Stolyarov K, Sysoeva T. Virus etiology of SARI cases and protective role of influenza vaccination determined in sentinel surveillance system. J Clin Virol 2015. [PMCID: PMC7172121 DOI: 10.1016/j.jcv.2015.07.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Meerhoff TJ, Simaku A, Ulqinaku D, Torosyan L, Gribkova N, Shimanovich V, Chakhunashvili G, Karseladze I, Yesmagambetova A, Kuatbayeva A, Nurmatov Z, Otorbaeva D, Lupulescu E, Popovici O, Smorodintseva E, Sominina A, Holubka O, Onyshchenko O, Brown CS, Gross D. Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region - an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC Infect Dis 2015; 15:1. [PMID: 25567701 PMCID: PMC4314771 DOI: 10.1186/s12879-014-0722-x] [Citation(s) in RCA: 111] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 12/17/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The 2009 H1N1 pandemic highlighted the need to routinely monitor severe influenza, which lead to the establishment of sentinel hospital-based surveillance of severe acute respiratory infections (SARI) in several countries in Europe. The objective of this study is to describe characteristics of SARI patients and to explore risk factors for a severe outcome in influenza-positive SARI patients. METHODS Data on hospitalised patients meeting a syndromic SARI case definition between 2009 and 2012 from nine countries in Eastern Europe (Albania, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Romania, Russian Federation and Ukraine) were included in this study. An exploratory analysis was performed to assess the association between risk factors and a severe (ICU, fatal) outcome in influenza-positive SARI patients using a multivariate logistic regression analysis. RESULTS Nine countries reported a total of 13,275 SARI patients. The majority of SARI patients reported in these countries were young children. A total of 12,673 SARI cases (95%) were tested for influenza virus and 3377 (27%) were laboratory confirmed. The majority of tested SARI cases were from Georgia, the Russian Federation and Ukraine and the least were from Kyrgyzstan. The proportion positive varied by country, season and age group, with a tendency to a higher proportion positive in the 15+ yrs age group in six of the countries. ICU admission and fatal outcome were most often recorded for influenza-positive SARI cases aged > 15 yrs. An exploratory analysis using pooled data from influenza-positive SARI cases in three countries showed that age > 15 yrs, having lung, heart, kidney or liver disease, and being pregnant were independently associated with a fatal outcome. CONCLUSIONS Countries in Eastern Europe have been able to collect data through routine monitoring of severe influenza and results on risk factors for a severe outcome in influenza-positive SARI cases have identified several risk groups. This is especially relevant in the light of an overall low vaccination uptake and antiviral use in Eastern Europe, since information on risk factors will help in targeting and prioritising vulnerable populations.
Collapse
Affiliation(s)
- Tamara J Meerhoff
- Department of Primary and Community Care, Radboud University Medical Centre, Nijmegen, the Netherlands.
| | | | | | - Liana Torosyan
- State Hygiene and Anti-epidemic Inspectorate, Yerevan, Armenia.
| | - Natalia Gribkova
- The Republican Research and Practical Center for Epidemiology and Microbiology (RRPCEM), Minsk, Belarus.
| | - Veronica Shimanovich
- The Republican Center for Hygiene, Epidemiology and Public Health, Minsk, Belarus.
| | | | - Irakli Karseladze
- National Centre for Disease Control and Public Health (NCDC), Tbilisi, Georgia.
| | | | - Ainagul Kuatbayeva
- Scientifical-Practical Center of Sanitary and Epidemiological Expertise and Monitoring, Almaty, Kazakhstan.
| | - Zuridin Nurmatov
- National Virological Laboratory, Department of the State Sanitary and Epidemiological Surveillance, Ministry of Health of Kyrgyz Republic, Bishkek, Kyrgyzstan.
| | - Dinagul Otorbaeva
- Department of State Sanitary Epidemiological Surveillance, Bishkek, Kyrgyzstan.
| | - Emilia Lupulescu
- Cantacuzino Institute, National Reference Centre for Influenza, Bucharest, Romania.
| | - Odette Popovici
- National Institute of Public Health, National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania.
| | - Elizaveta Smorodintseva
- National Influenza Centre at the Research Institute of Influenza, St Petersburg, Russian Federation.
| | - Anna Sominina
- National Influenza Centre at the Research Institute of Influenza, St Petersburg, Russian Federation.
| | - Olga Holubka
- L.V. Gromashevskyi Institute of Epidemiology and Infectious Diseases, Kiev, Ukraine.
| | - Olga Onyshchenko
- L.V. Gromashevskyi Institute of Epidemiology and Infectious Diseases, Kiev, Ukraine.
| | | | - Diane Gross
- WHO Regional Office for Europe, Copenhagen, Denmark.
| |
Collapse
|
20
|
Krivitskaya V, Sorokin E, Tsareva T, Petrova E, Konovalova N, Pisareva M, Buzitskaya Z, Smirnova T, Sominina A. Development of the cell-ELISA test for the subtype identification of circulating influenza A(H1) and A(H3) viruses. MIR journal 2015. [DOI: 10.18527/2500-2236-2015-2-1-65-68] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
21
|
Puig-Barberà J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, Buigues-Vila A, Martínez-Úbeda S, Sominina A. 2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network. PLoS One 2014; 9:e100497. [PMID: 24945510 PMCID: PMC4063939 DOI: 10.1371/journal.pone.0100497] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Accepted: 05/24/2014] [Indexed: 01/14/2023] Open
Abstract
Background The effectiveness of currently licensed vaccines against influenza has not been clearly established, especially among individuals at increased risk for complications from influenza. We used a test-negative approach to estimate influenza vaccine effectiveness (IVE) against hospitalization with laboratory-confirmed influenza based on data collected from the Global Influenza Hospital Surveillance Network (GIHSN). Methods and Findings This was a multi-center, prospective, active surveillance, hospital-based epidemiological study during the 2012–2013 influenza season. Data were collected from hospitals participating in the GIHSN, including five in Spain, five in France, and four in the Russian Federation. Influenza was confirmed by reverse transcription-polymerase chain reaction. IVE against hospitalization for laboratory-confirmed influenza was estimated for adult patients targeted for vaccination and who were swabbed within 7 days of symptom onset. The overall adjusted IVE was 33% (95% confidence interval [CI], 11% to 49%). Point estimates of IVE were 23% (95% CI, −26% to 53%) for influenza A(H1N1)pdm09, 30% (95% CI, −37% to 64%) for influenza A(H3N2), and 43% (95% CI, 17% to 60%) for influenza B/Yamagata. IVE estimates were similar in subjects <65 and ≥65 years of age (35% [95% CI, −15% to 63%] vs.31% [95% CI, 4% to 51%]). Heterogeneity in site-specific IVE estimates was high (I2 = 63.4%) for A(H1N1)pdm09 in patients ≥65 years of age. IVE estimates for influenza B/Yamagata were homogenous (I2 = 0.0%). Conclusions These results, which were based on data collected from the GIHSN during the 2012–2013 influenza season, showed that influenza vaccines provided low to moderate protection against hospital admission with laboratory-confirmed influenza in adults targeted for influenza vaccination. In this population, IVE estimates against A(H1N1)pdm09 were sensitive to age group and study site. Influenza vaccination was moderately effective in preventing admissions with influenza B/Yamagata for all sites and age groups.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO – Public Health, Valencia, Spain
- * E-mail:
| | - Angels Natividad-Sancho
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO – Public Health, Valencia, Spain
| | - Odile Launay
- Université Paris Descartes, Sorbonne Paris Cité, Inserm, CIC 1417 and the French Vaccine Research Network (REIVAC), Paris, France
| | - Elena Burtseva
- D.I. Ivanovsky Institute of Virology, Moscow, Russian Federation
| | - Meral A. Ciblak
- National Influenza Reference Laboratory Cappa-Istanbul, Istanbul, Turkey
| | - Anita Tormos
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO – Public Health, Valencia, Spain
| | - Amparo Buigues-Vila
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO – Public Health, Valencia, Spain
| | - Sergio Martínez-Úbeda
- Foundation for the Promotion of Health and Biomedical Research in the Valencia Region FISABIO – Public Health, Valencia, Spain
| | - Anna Sominina
- Research Institute of Influenza, St. Petersburg, Russian Federation
| | | |
Collapse
|
22
|
Puig-Barberà J, Tormos A, Sominina A, Burtseva E, Launay O, Ciblak MA, Natividad-Sancho A, Buigues-Vila A, Martínez-Úbeda S, Mahé C. First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health 2014; 14:564. [PMID: 24903737 PMCID: PMC4057821 DOI: 10.1186/1471-2458-14-564] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2014] [Accepted: 05/28/2014] [Indexed: 11/10/2022] Open
Abstract
Background The Global Influenza Hospital Surveillance Network (GIHSN) was developed to improve understanding of severe influenza infection, as represented by hospitalized cases. The GIHSN is composed of coordinating sites, mainly affiliated with health authorities, each of which supervises and compiles data from one to seven hospitals. This report describes the distribution of influenza viruses A(H1N1), A(H3N2), B/Victoria, and B/Yamagata resulting in hospitalization during 2012–2013, the network’s first year. Methods In 2012–2013, the GIHSN included 21 hospitals (five in Spain, five in France, four in the Russian Federation, and seven in Turkey). All hospitals used a reference protocol and core questionnaire to collect data, and data were consolidated at five coordinating sites. Influenza infection was confirmed by reverse-transcription polymerase chain reaction. Hospitalized patients admitted within 7 days of onset of influenza-like illness were included in the analysis. Results Of 5034 patients included with polymerase chain reaction results, 1545 (30.7%) were positive for influenza. Influenza A(H1N1), A(H3N2), and both B lineages co-circulated, although distributions varied greatly between coordinating sites and over time. All age groups were affected. A(H1N1) was the most common influenza strain isolated among hospitalized adults 18–64 years of age at four of five coordinating sites, whereas A(H3N2) and B viruses were isolated more often than A(H1N1) in adults ≥65 years of age at all five coordinating sites. A total of 16 deaths and 20 intensive care unit admissions were recorded among patients with influenza. Conclusions Influenza strains resulting in hospitalization varied greatly between coordinating sites and over time. These first-year results of the GIHSN are relevant, useful, and timely. Due to its broad regional representativeness and sustainable framework, this growing network should contribute substantially to understanding the epidemiology of influenza, particularly for more severe disease.
Collapse
Affiliation(s)
- Joan Puig-Barberà
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO-Salud Pública), Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Khan AS, Polezhaev F, Vasiljeva R, Drinevsky V, Buffington J, Gary H, Sominina A, Keitel W, Regnery H, Lonskaya NL, Doroshenko E, Gavrilov A, Ivakhov I, Arden N, Schonberger LB, Couch R, Kendal A, Cox N. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis 1996; 173:453-6. [PMID: 8568310 DOI: 10.1093/infdis/173.2.453] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
In a blinded, placebo-controlled study, the reactogenicity, immunogenicity, and clinical efficacy of single doses of US inactivated split-virus and Russian live attenuated, cold-adapted influenza vaccines were compared in 555 schoolchildren in Vologda, Russia. Serial serum samples were collected and school absenteeism was assessed. Systemic reactions were rare, but local reactions (primarily erythema at the injection site) were observed in 27% of the inactivated vaccine group, and coryza (12%) and sore throat (8%) were observed in the attenuated vaccine group. At 4 weeks after vaccination a > or = 4-fold rise in titer of hemagglutination inhibition antibody to A (H1N1), A (H3N2), and B was noted, respectively, among 78%, 88%, and 53% of children who received inactivated vaccine and among 55%, 79%, and 30% of children who received attenuated vaccine. The vaccine efficacy for preventing school absenteeism due to respiratory illness during the period of peak influenza activity was 56% for inactivated vaccine and 47% for attenuated vaccine.
Collapse
Affiliation(s)
- A S Khan
- Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|